• Register
  • Login

European Journal of Molecular & Clinical Medicine

  1. Home
  2. Assessment of efficacy of tadalafil with tamsulosin in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia

Current Issue

By Issue

By Author

By Subject

Author Index

Keyword Index

About Journal

Aims and Scope

Editorial Board

Publication Ethics

Indexing and Abstracting

Related Links

FAQ

Peer Review Process

Journal Metrics

News

Assessment of efficacy of tadalafil with tamsulosin in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia

    Author

    • Dr. Yogesh Ramakant Jadhav, Dr Abhijit R. Katkar, Dr. Asit Choudhary, Dr Prasad Hake
,

Document Type : Research Article

  • Article Information
  • Download
  • Export Citation
  • Statistics
  • Share

Abstract

Background: Benign prostatic hyperplasia (BPH) is highly prevalent in elderly men and often results in lower urinary tract symptoms (LUTS). The present study was conducted to compare the efficacy of tadalafil with tamsulosin in the treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).
Materials & Methods: 78 patients of diagnosed with LUTS secondary toBPHwere divided into 2 groups. Group I were given tadalafil 5 mg and group II tamsulosin 0.4 mg. Maximum flow rate (Qmax), Postvoid residual urine (PVR), International Prostate Symptom Score (IPSS), International Prostate Symptom Score Quality of life (IPSS QoL) and Sexual Health Inventory for Men (SHIM) scoring were compared.
Results: mean prostate size in group I was 32.5 gram and in group II was 30.1 gram. Qmax was 13.6 ml/sec in group I and 12.8 ml/sec in group II. PVR was 51.4 ml in group I and 83.2 ml in group II. IPSS was 12.7 in group I and 14.9 in group II, IPSS QoL was 2.3 in group I and 3.0 in group II. The difference was significant (P< 0.05).
Conclusion: Once daily tadalafil 5 mg is well tolerated and can be considered for the treatment of LUTS secondary to BPH when associated with ED

Keywords

  • Benign Prostatic Hyperplasia
  • Lower urinary tract symptoms
  • Men
  • XML
  • PDF 194.86 K
  • RIS
  • EndNote
  • Mendeley
  • BibTeX
  • APA
  • MLA
  • HARVARD
  • VANCOUVER
    • Article View: 17
    • PDF Download: 74
European Journal of Molecular & Clinical Medicine
Volume 9, Issue 7
September 2022
Page 5745-5748
Files
  • XML
  • PDF 194.86 K
Share
Export Citation
  • RIS
  • EndNote
  • Mendeley
  • BibTeX
  • APA
  • MLA
  • HARVARD
  • VANCOUVER
Statistics
  • Article View: 17
  • PDF Download: 74

APA

Dr Prasad Hake, D. Y. R. J. D. A. R. K. D. A. C. (2022). Assessment of efficacy of tadalafil with tamsulosin in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. European Journal of Molecular & Clinical Medicine, 9(7), 5745-5748.

MLA

Dr. Yogesh Ramakant Jadhav, Dr Abhijit R. Katkar, Dr. Asit Choudhary, Dr Prasad Hake. "Assessment of efficacy of tadalafil with tamsulosin in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia". European Journal of Molecular & Clinical Medicine, 9, 7, 2022, 5745-5748.

HARVARD

Dr Prasad Hake, D. Y. R. J. D. A. R. K. D. A. C. (2022). 'Assessment of efficacy of tadalafil with tamsulosin in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia', European Journal of Molecular & Clinical Medicine, 9(7), pp. 5745-5748.

VANCOUVER

Dr Prasad Hake, D. Y. R. J. D. A. R. K. D. A. C. Assessment of efficacy of tadalafil with tamsulosin in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. European Journal of Molecular & Clinical Medicine, 2022; 9(7): 5745-5748.

  • Home
  • About Journal
  • Editorial Board
  • Submit Manuscript
  • Contact Us
  • Glossary
  • Sitemap

News

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

Newsletter Subscription

Subscribe to the journal newsletter and receive the latest news and updates

© Journal Management System. Powered by ejournalplus